Wan, Z.; Wang, C.; Luo, S.; Zhu, J.; He, H.; Hao, K.
Bridging the Gap Between hiPSC-CMs Cardiotoxicity Assessment and Clinical LVEF Decline Risk: A Case Study of 21 Tyrosine Kinase Inhibitors. Pharmaceuticals 2025, 18, 450.
https://doi.org/10.3390/ph18040450
AMA Style
Wan Z, Wang C, Luo S, Zhu J, He H, Hao K.
Bridging the Gap Between hiPSC-CMs Cardiotoxicity Assessment and Clinical LVEF Decline Risk: A Case Study of 21 Tyrosine Kinase Inhibitors. Pharmaceuticals. 2025; 18(4):450.
https://doi.org/10.3390/ph18040450
Chicago/Turabian Style
Wan, Zhijie, Chenyu Wang, Shizheng Luo, Jinwei Zhu, Hua He, and Kun Hao.
2025. "Bridging the Gap Between hiPSC-CMs Cardiotoxicity Assessment and Clinical LVEF Decline Risk: A Case Study of 21 Tyrosine Kinase Inhibitors" Pharmaceuticals 18, no. 4: 450.
https://doi.org/10.3390/ph18040450
APA Style
Wan, Z., Wang, C., Luo, S., Zhu, J., He, H., & Hao, K.
(2025). Bridging the Gap Between hiPSC-CMs Cardiotoxicity Assessment and Clinical LVEF Decline Risk: A Case Study of 21 Tyrosine Kinase Inhibitors. Pharmaceuticals, 18(4), 450.
https://doi.org/10.3390/ph18040450